Literature DB >> 31525474

Dissecting the mechanisms of bone loss in Gorham-Stout disease.

Michela Rossi1, Paola Sabrina Buonuomo2, Giulia Battafarano1, Antonella Conforti3, Eda Mariani4, Mattia Algeri3, Simone Pelle5, Matteo D'Agostini6, Marina Macchiaiolo2, Rita De Vito7, Michaela Veronika Gonfiantini2, Alessandro Jenkner8, Ippolita Rana2, Andrea Bartuli2, Andrea Del Fattore9.   

Abstract

Gorham-Stout disease (GSD) is a rare disorder characterized by progressive osteolysis and angiomatous proliferation. Since the mechanisms leading to bone loss in GSD are not completely understood, we performed histological, serum, cellular and molecular analyses of 7 patients. Increased vessels, osteoclast number and osteocyte lacunar area were revealed in patients' bone biopsies. Biochemical analysis of sera showed high levels of ICTP, Sclerostin, VEGF-A and IL-6. In vitro experiments revealed increased osteoclast differentiation and activity, and impaired mineralization ability of osteoblasts. To evaluate the involvement of systemic factors in GSD, control cells were treated with patients' sera and displayed an increase of osteoclastogenesis, bone resorption activity and a reduction of osteoblast function. Interestingly, GSD sera stimulated the vessel formation by endothelial cells EA.hy926. These results suggest that bone cell autonomous alterations with the cooperation of systemic factors are involved in massive bone loss and angiomatous proliferation observed in GSD patients.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bone histomorphometry; Gorham-Stout disease; Osteoblast; Osteoclast; Osteolysis

Mesh:

Year:  2019        PMID: 31525474     DOI: 10.1016/j.bone.2019.115068

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  8 in total

Review 1.  Current concepts from diagnosis to management in Gorham-Stout disease: a systematic narrative review of about 350 cases.

Authors:  Andrea Angelini; Nicolò Mosele; Elisa Pagliarini; Pietro Ruggieri
Journal:  EFORT Open Rev       Date:  2022-01-11

Review 2.  Genetic and Molecular Determinants of Lymphatic Malformations: Potential Targets for Therapy.

Authors:  Su Yeon Lee; Emma Grace Loll; Abd-Elrahman Said Hassan; Mingyu Cheng; Aijun Wang; Diana Lee Farmer
Journal:  J Dev Biol       Date:  2022-02-08

3.  Refractory serositis in Gorham-Stout syndrome.

Authors:  Hong Di; Bingqing Zhang; Na Xu; Yue Yin; Xinxin Han; Yun Zhang; Xuejun Zeng
Journal:  Orphanet J Rare Dis       Date:  2022-04-04       Impact factor: 4.123

Review 4.  Osteopathy in Complex Lymphatic Anomalies.

Authors:  Ernesto Solorzano; Andrew L Alejo; Hope C Ball; Joseph Magoline; Yusuf Khalil; Michael Kelly; Fayez F Safadi
Journal:  Int J Mol Sci       Date:  2022-07-26       Impact factor: 6.208

Review 5.  Difficult Therapeutic Decisions in Gorham-Stout Disease-Case Report and Review of the Literature.

Authors:  Katarzyna Wojciechowska-Durczynska; Arkadiusz Zygmunt; Marta Mikulak; Marta Ludwisiak; Andrzej Lewinski
Journal:  Int J Environ Res Public Health       Date:  2022-09-16       Impact factor: 4.614

Review 6.  A Large Skull Defect Due to Gorham-Stout Disease: Case Report and Literature Review on Pathogenesis, Diagnosis, and Treatment.

Authors:  Catherine E de Keyser; Michael S Saltzherr; Eelke M Bos; M Carola Zillikens
Journal:  Front Endocrinol (Lausanne)       Date:  2020-02-05       Impact factor: 5.555

Review 7.  Gorham-Stout disease successfully treated with sirolimus (rapamycin): a case report and review of the literature.

Authors:  Yu Liang; Ruicheng Tian; Jing Wang; Yuhua Shan; Hongxiang Gao; Chenjie Xie; Jingjing Li; Min Xu; Song Gu
Journal:  BMC Musculoskelet Disord       Date:  2020-08-25       Impact factor: 2.362

8.  Usefulness of 99mTc-ASC lymphoscintigraphy and SPECT/CT in the evaluation of rare lymphatic disorders: Gorham-Stout disease, lymphangioma, and lymphangioleiomyomatosis.

Authors:  Guozhu Hou; Yuanyuan Jiang; Hongli Jing; Wenshuai Xu; Kai-Feng Xu; Libo Chen; Fang Li; Wuying Cheng
Journal:  Medicine (Baltimore)       Date:  2020-09-25       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.